Amoéba postpones biocontrol applications in the U.S., commercialization slightly delayed

In France, Amoéba announces its 2020 half-year results which were in line with those of 2019 and continues to develop its biocide and biocontrol applications, albeit with some areas slightly delayed such as the application for the marketing of the biocide activity in the United States, previously planned for mid-2020 is postponed and will be submitted at the end of 2020.

The commercialization of biocontrol products containing the active substance (amoeba Willaertia magna C2c Maky amoeba lysate) is envisaged by Amoeba in 2024 in Europe and in the first half of 2022 in the United States (submission envisaged in July 2020, postponed to September 2020).

As the Company’s Regulatory Affairs department worked on the marketing authorization of the biocontrol application as a priority, the application for the marketing of the biocide activity in the United States, previously planned for mid-2020 has been postponed and will be submitted at the end of 2020 with a first marketing in the United States estimated for the first half of 2022.

Amoéba is receiving numerous requests to integrate its solution into existing applications (biocide and biocontrol) in new fields.